| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC25A39 |
| Uniprot No | Q9BZJ4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-359aa |
| 氨基酸序列 | MADQDPAGISPLQQMVASGTGAVVTSLFMTPLDVVKVRLQSQRPSMASELMPSSRLWSLSYTKLPSSLQSTGKCLLYCNGVLEPLYLCPNGARCATWFQDPTRFTGTMDAFVKIVRHEGTRTLWSGLPATLVMTVPATAIYFTAYDQLKAFLCGRALTSDLYAPMVAGALARLGTVTVISPLELMRTKLQAQHVSYRELGACVRTAVAQGGWRSLWLGWGPTALRDVPFSALYWFNYELVKSWLNGFRPKDQTSVGMSFVAGGISGTVAAVLTLPFDVVKTQRQVALGAMEAVRVNPLHVDSTWLLLRRIRAESGTKGLFAGFLPRIIKAAPSCAIMISTYEFGKSFFQRLNQDRLLGG |
| 预测分子量 | 39,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"SLC25A39 is necessary for mitochondrial glutathione import in mammalian cells"**
- **作者**: Chen et al., 2021
- **摘要**: 研究通过重组人源SLC25A39蛋白的功能分析，揭示其在线粒体谷胱甘肽转运中的关键作用，并验证其缺失导致氧化应激敏感性增加。
2. **"Structural basis of SLC25A39 activity in iron homeostasis"**
- **作者**: Zhang et al., 2022
- **摘要**: 利用重组SLC25A39蛋白的冷冻电镜结构解析，阐明其底物结合域特征及在铁代谢中的分子机制。
3. **"SLC25A39 deletion disrupts cellular heme biosynthesis via mitochondrial transport"**
- **作者**: Wang et al., 2023
- **摘要**: 通过重组蛋白体外实验，证明SLC25A39参与血红素前体运输，其缺失导致线粒体代谢通路异常。
4. **"Mitochondrial SLC25A39 modulates cellular iron trafficking and stress response"**
- **作者**: Hughes et al., 2021
- **摘要**: 研究重组SLC25A39蛋白的体外功能，发现其通过调控铁硫簇合成影响细胞铁稳态及氧化应激应答。
(注：以上文献为示例，实际引用需以真实发表论文为准。)
SLC25A39 is a member of the solute carrier family 25 (SLC25), a group of mitochondrial carrier proteins responsible for transporting metabolites, nucleotides, amino acids, and lipids across the mitochondrial inner membrane. These transporters play critical roles in maintaining cellular energy production, redox balance, and metabolic homeostasis. SLC25A39. specifically, has garnered attention for its potential involvement in mitochondrial glutathione (GSH) metabolism. GSH is a key antioxidant that protects cells from oxidative damage, and its mitochondrial pool is essential for maintaining proper redox signaling and preventing oxidative stress-induced cell death. Although the exact substrate specificity of SLC25A39 remains under investigation, studies suggest it may facilitate GSH transport into mitochondria or regulate GSH homeostasis through indirect mechanisms.
Recombinant SLC25A39 protein is engineered for in vitro studies to elucidate its biochemical properties, structural features, and interaction partners. It is typically produced using heterologous expression systems, such as *E. coli* or mammalian cell cultures, followed by purification via affinity tags (e.g., His-tag). This recombinant tool enables researchers to analyze transport kinetics, substrate binding, and the impact of mutations on protein function. Structural studies, including cryo-EM or X-ray crystallography, aim to resolve its 3D conformation, providing insights into its transport mechanism.
Dysregulation of SLC25A39 has been linked to pathologies such as anemia, neurodegenerative disorders, and cancer, highlighting its physiological relevance. For example, in mammals, SLC25A39 deficiency disrupts mitochondrial iron-sulfur cluster biogenesis, impairing erythroid development. Recombinant SLC25A39 also serves as a reagent for drug screening, targeting mitochondrial dysfunction in diseases. Ongoing research focuses on its role in metabolic adaptation, aging, and response to oxidative stress, positioning it as a potential therapeutic target for conditions involving mitochondrial redox imbalance.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
